Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Jesse 2009 CNS Neurosci Ther

From Bioblast
Revision as of 16:08, 17 September 2010 by Biljana (talk | contribs) (Created page with "{{Publication |title=Jesse S, Steinacker P, Lehnert S, Gillardon F, Hengerer B, Otto M (2009) Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson deme...")
(diff) ← Older revision | Latest revision (diff) | Newer revision β†’ (diff)
Publications in the MiPMap
Jesse S, Steinacker P, Lehnert S, Gillardon F, Hengerer B, Otto M (2009) Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review. CNS Neurosci. Ther. 15: 157-182.

Β» PMID: 19298613

Jesse S, Steinacker P, Lehnert S, Gillardon F, Hengerer B, Otto M (2009) CNS Neuroscience & Therapeutics

Abstract: The diagnosis of Parkinson disease (PD) is rendered on the basis of clinical parameters, whereby laboratory chemical tests or morphological imaging is only called upon to exclude other neurodegenerative diseases. The differentiation between PD and other diseases of the basal ganglia, especially the postsynaptic Parkinson syndromes multisystem atrophy (MSA) and progressive supranuclear palsy (PSP), is of decisive importance, on the one hand, for the response to an appropriate therapy, and on the other hand, for the respective prognosis of the disease. However, particularly at the onset of symptoms, it is difficult to precisely distinguish these diseases from each other, presenting with an akinetic-rigid syndrome. It is not yet possible to conduct a neurochemical differentiation of Parkinson syndromes. Therefore, a reliable biomarker is still to be found that might predict the development of Parkinson dementia. Since this situation is currently the subject of various different studies, the following synopsis is intended to provide a brief summary of the investigations addressing the field of the early neurochemical differential diagnosis of Parkinson syndromes and the early diagnosis of Parkinson dementia, from direct Ξ±-synuclein detection to proteomic approaches. In addition, an overview of the tested biomarkers will be given with regard to their possible introduction as a screening method. β€’ Keywords: Differential diagnosis, Multisystem atrophy, Neurochemical diagnosis, Parkinson dementia, Parkinson disease, Progressive supranuclear palsy


Labels:




Regulation: Respiration; OXPHOS; ETS Capacity"Respiration; OXPHOS; ETS Capacity" is not in the list (Aerobic glycolysis, ADP, ATP, ATP production, AMP, Calcium, Coupling efficiency;uncoupling, Cyt c, Flux control, Inhibitor, ...) of allowed values for the "Respiration and regulation" property. 


HRR: Oxygraph-2k